Adamax vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Adamax
Adamax is a modified version of Semax with an adamantane group attached, designed to enhance its nootropic effects and extend duration of action compared to standard Semax.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | Adamax | Substance P |
|---|---|---|
| Mechanism | Similar to Semax - enhances BDNF expression and modulates dopamine/serotonin systems. The adamantane modification may increase lipophilicity and CNS penetration. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | Intranasal: 100-500mcg 1-2 times daily. Lower doses than standard Semax may be effective due to enhanced potency. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Intranasal spray is most common route. More stable than standard Semax. Often used for acute cognitive enhancement. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Similar to Semax - possible irritability, hair shedding, or overstimulation. May have stronger effects than standard Semax. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |
What They Have in Common
Both Adamax and Substance P are commonly used for: